IPSEF:OTC-Ipsen S.A (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 103.5

Change

0.00 (0.00)%

Market Cap

USD 9.50B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-05 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+0.02 (+0.01%)

USD 72.38B
HLN Haleon plc

+0.19 (+1.74%)

USD 50.16B
TAK Takeda Pharmaceutical Co Ltd A..

-0.04 (-0.27%)

USD 44.08B
RDY Dr. Reddy’s Laboratories Ltd..

+0.78 (+5.29%)

USD 11.96B
ELAN Elanco Animal Health

-0.01 (-0.07%)

USD 6.42B
AMRX Amneal Pharmaceuticals, Inc. C..

-0.04 (-0.55%)

USD 3.54B
BHC Bausch Health Companies Inc

-0.01 (-0.22%)

USD 1.73B
YCBD cbdMD Inc

+0.01 (+1.51%)

USD 8.19M
CPHI China Pharma Holdings Inc

-0.13 (-7.88%)

USD 7.24M
EBS Emergent Biosolutions Inc

-0.28 (-4.42%)

N/A

ETFs Containing IPSEF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -17.44% 27% F 12% F
Dividend Return 2.44% 100% F 76% C+
Total Return -15.00% 27% F 13% F
Trailing 12 Months  
Capital Gain -21.89% 20% F 12% F
Dividend Return 2.31% 43% F 45% F
Total Return -19.58% 20% F 12% F
Trailing 5 Years  
Capital Gain 47.22% 93% A 64% D
Dividend Return 12.71% 50% F 37% F
Total Return 59.93% 86% B+ 60% D-
Average Annual (5 Year Horizon)  
Capital Gain 7.51% 66% D+ 57% F
Dividend Return 8.82% 66% D+ 54% F
Total Return 1.31% 50% F 32% F
Risk Return Profile  
Volatility (Standard Deviation) 16.75% 98% N/A 90% A-
Risk Adjusted Return 52.63% 95% A 86% B+
Market Capitalization 9.50B 60% D- 85% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.